A Phase II exploratory study of Ipilimumab N01 in combination with Sintilimab and platinum-based chemotherapy as first-line treatment for locally advanced or metastatic NSCLC with SMARCA4 mutation or deficiency, or STK11/KEAP1 mutations

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 94e1692c192da66383b85e5eb5b3a7e2cd59ac76
First added on: Oct 10, 2026